source
- AstraZeneca explores options after anselamimab fails Phase 3, while Imfinzi and Tremfya receive label expansionsAstraZeneca announced that its experimental monoclonal antibody anselamimab failed to meet the primary endpoint in two Phase 3 trials for a specific patient group. The company said it will explore…
- Agios halts development of tebapivat for low-risk MDS after disappointing Phase 2b dataAgios Pharmaceuticals announced it will discontinue development of its pyruvate kinase activator tebapivat for patients with low-risk myelodysplastic syndromes (MDS). The decision follows the relea…